Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Part 2 Revision > Polyoma > Flashcards

Polyoma Flashcards

1
Q

Name other Polyomaviruses than BK/JC

A

Ki and Wu (respiratory), Merkel cell polyomavirus, Trichodysplasia spinulosa virus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the name of the polyomavirus antigen involved in infection?

A

Large T

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the receptor for JC virus?

A

Alpha-2,6 sialic acid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

In which tissues is JC latent?

A

Tonsillar, renal tubular cells, bone marrow, brain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What does JC virus isolated from PML look like?

A

Highly variable genomic rearragnements of noncoding control region (JC architype is shed in urine and doesn’t cause disease)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How does primary JC/BK infection present and what is seroprevelence?

A

Mild respiratory symptoms, or asympotmatic, most infections during childhood and JC 50% seroprevelance by teen years, Bk 80%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What groups are at risk of reactivation of JC?

A

Reactivation is common in all people, and 30% shed in urine asymptomaticlaly but immunosuppressed patients are at risk of reactivation and disease. AIDS (80%), Haematological malignancies (13%), SOT/BMT (5%), chronic inflammatory disease (2%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Clinical featres of JC virus

A

Asymptomatic, PML, other nuerologies: JC-granule cell neuropathy, JCV encephalopathy, JCV meningitis. JC associated nephropathy in kidney transplant, ?implicated in colorectal carcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Clinical features of PML

A

Insidous onset and steady progression. Progressive demyelination of white matter. Cognitiive deterioration, gait and coordination abnormalities, limb paresis and seizures

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

In PML what does CT/MRI show

A

White matter lesions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the three states of PML?

A

1) PML due to immune suppression 2) PML/IRIS at the same time upon immunereconstitution 3)PML-IRIS - worsening of existing PML due to IRIS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

PML-IRIS, who is at risk? Symptoms? Treatment?

A

Can occur on initiation of ART or during plasma exchange in MS patients on natalizumab. Acute onset, odema, mass effect. Treated with corticosteroids, or maraviroc

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What groups are at risk of PML?

A

BMT, SOT, AIDS, leucaemia, inflammatory malignancies, CD4 lymphocytopaenia, mAbs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Which mAbs increase the risk of reactivation of BK/JC and could lead to PML?

A

Natalizumab (MS). Efalizumab (psoriasis) rituximab, JAK inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the risk factors for PML in patients using natalizumab?

A

1) JC virus antibody (>1.5) 2) Prior immunosuppression 3) Treatment duration (>2 years)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the wash out period of natalizumab?

A

3 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What test is used for the antibody index of JC?

A

STRATIFY JC assay (Focus diagnostics)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

When is MRI used in natalizumab use?

A

At baseline and then 1) annually if low risk 2) 6 monthly if intermediate risk 3) 3 monthly if high risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

In patients with JC AI >1.5 what is their risk of PML after 2 years?

A

1 in 113

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

When is JC anitbody index tested in natalizumab use?

A

At baseline, then no testing for 12 m. Then 1) if <1.5 test 6 monthly 2) if >1.5 no further testing

21
Q

Kidney transplant patient with nephropathy - BK virus negative in urine and blood, but SV40 staining positiive in biopsy. What are the next steps?

A

Test JC virus in urine (high VL) and blood (often low level or undetectable). Reduction of immunosuppression and IVIG if no resolution of symptoms

22
Q

What would you see in a brain biopsy in a patient with PML

A

Intranuclear inclusions, bizarre astrocytes, lipid laden macrophages, SV40 positive

23
Q

When and how would you use quantitiative PCR for JCV?

A

Monitoring JCV VL in CSF in patients on ART/removal of mAbs. NIBSC have WHO 1st international standard

24
Q

What is sens/spec for PML in CSF/blood/biopsy?

A

CSF = 72-92% sens, 92-100% specific. Blood 40% sesitivity, 92% specificity. Brain bx = 64-96% sensitvity 100% specificity

25
Q

What treatment is available for PML?

A

Reduction of immunosuppression or ART. Reconstitution of CD4/CD8 T cells are crititcal for halting progression of PML.

26
Q

Name four novel therapys for PML

A

1) JC /BK specific T cell therapy 2) Checkpoint inhibitors (PD-1 mAb) 3) hrIL-7 4) Mirtazipine (5HT2AR)

27
Q

Where does BK remain latent?

A

Renal tubular epithelial cells

28
Q

What are risk factors for BK disease?

A

Immunosuppression plus high BK virus IgG titre pre trasnplant, older age

29
Q

Clinical features of BK infection?

A

BK associated nephropathy (renal tx patients), haemorrhagic cystitis (BMT patients) other rare presentations - pneumonitis, retinitis, liver disease, meningoencephalitis, PML

30
Q

What is the risk of BKVAN casuing allograft failure in renal tx patients and when is this most likely to occur?

A

1-10% risk of allograft failure, 3% chance of ureteral stenosis = average diagnosis at 44 weeks

31
Q

What % of renal transplant patients have BK viruria and how many of these will go on to develop BKVAN?

A

80% with viruria and 5-10% will develop BKVAN

32
Q

Does BKV screening in urine have a good PPV/NPV?

A

Excellent NPV but poor PPV, can be useful for early detection

33
Q

What is the policy for screening for BKVAN in renal tx patients?

A

VL in plasma monthly until 9 m post transnplant and then 3 monthly for 2 years.

34
Q

At what level of BKV in plamsa in renal tx pateints would you intervene?

A

If VL 1000-10000 copies/ml then repeat and confirm at 2-3 weeks , if sustained at >1000 then continue to monitor at 2-4 weeks. If >10000 then reduce IS

35
Q

When would you perform a renal biopsy in BK virus?

A

Never without evidence of renal function disorder. E.g. altered renal function, increase in serum creatinine, haematuria or proteinuria)

36
Q

What would you observe in a biopsy of BKVAN?

A

Severe tubular damage, interstitial inflammation, tubulitis, interstitial fibrosis. SV40 positiive (but false neg do occur in early infection) Use Banff ci-score for pathology

37
Q

How do you monitor BKVAN post reduction of immunosuppression?

A

Plasma viral load negativity can be used to show resolution of nephropathy

38
Q

Differential diagnosis of BKVAN

A

Allograft rejection, JC, adenovirus, CMV, HSV

39
Q

If resolution of BKVAN does not occur after reducation of immunosuppression what are the next steps?

A

Addition of IVIG and finally re-transplantation

40
Q

What is the risk of haemorrhagic cystitis due to BK in BMT patients?

A

10-25%

41
Q

What are symptoms of BK virus in BMT patients

A

Haematuria, dysuria, urgency and frequency, suprapubic pain

42
Q

When is BK haemorrhagic cystitis most likely to occur in BMT patients?

A

2-8 weeks post tx - can be 1 week to 8 months

43
Q

What are the differential diagnosis for haemorrhagic cystitis in BMT patients?

A

BK, direct toxicity, CMV, adenovirus, JC and HSV are rare causes

44
Q

What is the diagnostic triad of BKV haemorrhagic cystitis in HSCT?

A

1) Cystitis 2) Grade 2+ haematuria 3) viruria >log 7

45
Q

What screening is implemented for BK virus in HSCT?

A

No asymptomatic screening

46
Q

What are the VL cut offs associated with highest risk/specificity for BK haemorrhagic cystitis?

A

Plasma VL 3-4 log copies/ml, and >log 7 viruria

47
Q

Treatment options for BK associated haemorrhagic cystitis

A

It generally resolves on its own, so only supportive management - hyperhydration, bladder irrigation, platelet transfusion and pain treatment. Cidofovir (with probenecid) could be considered but data not great. Reduction of immunosuppression is not routine due to risk of rejection, can be considered if benefit outweighs risk

48
Q

What are decoy cells?

A

BK infected renal tubular epithelial cells shed in urine, show basophilic inclusions with pap stain. 100% sensitivity but only 20% specificity as seen in JC and adeno infection

49
Q

What is NPV/PPV in plasma for BKVAN?

A

100% NPV and 50% PPV

Part 2 Revision (37 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions